{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T06:02:12Z","timestamp":1771394532882,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.modpat.2025.100954","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:05:16Z","timestamp":1766793916000},"page":"100954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lowering the Diagnostic Threshold in Secondary Plasma Cell Leukemia? Comparison With Primary Cases and Implications for Flow Cytometry Immunophenotyping"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7731-7186","authenticated-orcid":false,"given":"Wen","family":"Shuai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Cameron","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawen","family":"Sui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nourhan","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zenggang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. James","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keyur P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.modpat.2025.100954_bib1","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: Consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fern\u00e1ndez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.modpat.2025.100954_bib2","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3324\/haematol.2016.158303","article-title":"Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition","volume":"102","author":"Granell","year":"2017","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.modpat.2025.100954_bib3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-018-0140-1","article-title":"Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.modpat.2025.100954_bib4","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.22.01226","article-title":"More than 2% of circulating tumor plasma cells defines plasma cell leukemia-like multiple myeloma","volume":"41","author":"Jelinek","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.modpat.2025.100954_bib5","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.22.02114","article-title":"How we manage newly diagnosed multiple myeloma with circulating tumor cells","volume":"41","author":"van de Donk","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2025.100954_bib6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pathol.2021.09.011","article-title":"The many faces of plasma cell neoplasms: morphological and immunophenotypical variants of the great imitator","volume":"54","author":"El Hussein","year":"2022","journal-title":"Pathology"},{"issue":"5","key":"10.1016\/j.modpat.2025.100954_bib7","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/cyto.b.21844","article-title":"Flow cytometric immunophenotypic analysis in the diagnosis and prognostication of plasma cell neoplasms","volume":"96","author":"Wang","year":"2019","journal-title":"Cytometry Part B, Clinical cytometry"},{"issue":"1","key":"10.1016\/j.modpat.2025.100954_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bjh.17713","article-title":"Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia","volume":"195","author":"Bezdekova","year":"2021","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.modpat.2025.100954_bib9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Sanoja-Flores","year":"2018","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.modpat.2025.100954_bib10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/leu.2016.205","article-title":"Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression","volume":"31","author":"Gonsalves","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.modpat.2025.100954_bib11","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/bjh.13484","article-title":"Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics","volume":"170","author":"Vagnoni","year":"2015","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.modpat.2025.100954_bib12","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/leu.2014.98","article-title":"Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma","volume":"28","author":"Gonsalves","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.modpat.2025.100954_bib13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.mayocp.2020.06.060","article-title":"Clinical characteristics and outcomes of patients with primary plasma cell leukemia in the era of novel agent therapy","volume":"96","author":"Nandakumar","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"17","key":"10.1016\/j.modpat.2025.100954_bib14","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1182\/blood.2021014968","article-title":"Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features","volume":"139","author":"Cazaubiel","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.modpat.2025.100954_bib15","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2008.4","article-title":"Genetic aberrations and survival in plasma cell leukemia","volume":"22","author":"Tiedemann","year":"2008","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.modpat.2025.100954_bib16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.anndiagpath.2005.12.011","article-title":"Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation","volume":"10","author":"Johnson","year":"2006","journal-title":"Ann Diagn Pathol"},{"issue":"6","key":"10.1016\/j.modpat.2025.100954_bib17","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bjh.15092","article-title":"Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients","volume":"180","author":"Jurczyszyn","year":"2018","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1016\/j.modpat.2025.100954_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70192","article-title":"Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia","volume":"13","author":"Tessier","year":"2024","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.modpat.2025.100954_bib19","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/cncr.31718","article-title":"Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents","volume":"125","author":"Mina","year":"2019","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.modpat.2025.100954_bib20","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/leu.2011.312","article-title":"Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research","volume":"26","author":"Mahindra","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.modpat.2025.100954_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/cyto.b.21228","article-title":"Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting","volume":"90","author":"Arroz","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"10.1016\/j.modpat.2025.100954_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jmoldx.2018.08.002","article-title":"Ultra-rapid reporting of GENomic targets (URGENTseq): clinical next-generation sequencing results within 48 hours of sample collection","volume":"21","author":"Patel","year":"2019","journal-title":"J Mol Diagn"},{"issue":"2","key":"10.1016\/j.modpat.2025.100954_bib23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival","volume":"101","author":"Turesson","year":"2018","journal-title":"Eur J Haematol"},{"issue":"27","key":"10.1016\/j.modpat.2025.100954_bib24","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma","volume":"40","author":"Garc\u00e9s","year":"2022","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.modpat.2025.100954_bib25","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.21.01393","article-title":"High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"40","author":"Bertamini","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.modpat.2025.100954_bib26","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1038\/sj.leu.2401211","article-title":"The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma","volume":"12","author":"Pellat-Deceunynck","year":"1998","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.modpat.2025.100954_bib27","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1046\/j.1365-2141.2002.03513.x","article-title":"Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma","volume":"117","author":"Sahara","year":"2002","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.modpat.2025.100954_bib28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3390\/biomedicines10020209","article-title":"The cytogenetic profile of primary and secondary plasma cell leukemia: etiopathogenetic perspectives, prognostic impact and clinical relevance to newly diagnosed multiple myeloma with differential circulating clonal plasma cells","volume":"10","author":"Papadhimitriou","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.modpat.2025.100954_bib29","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/10428194.2018.1473574","article-title":"Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients","volume":"60","author":"Jurczyszyn","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.modpat.2025.100954_bib30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clml.2024.10.014","article-title":"Clinical characteristics and survival outcomes of patients with primary and secondary plasma cell leukemia according to the 2021 definition: A single center retrospective study","volume":"25","author":"Shalaby","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.modpat.2025.100954_bib31","first-page":"77","article-title":"Single-center experience of patients with plasma cell leukemia in the era of new therapeutics","volume":"148","author":"Dampmann","year":"2025","journal-title":"Acta Haematol"},{"issue":"3","key":"10.1016\/j.modpat.2025.100954_bib32","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.V97.3.822","volume":"97","author":"Avet-Loiseau","year":"2001","journal-title":"Blood"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395225002522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395225002522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:03:47Z","timestamp":1771391027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395225002522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0893395225002522"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2025.100954","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lowering the Diagnostic Threshold in Secondary Plasma Cell Leukemia? Comparison With Primary Cases and Implications for Flow Cytometry Immunophenotyping","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2025.100954","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100954"}}